Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Hepatosys Inc
Profile last edited on: 1/10/17      CAGE: 47V07      UEI:

Business Identifier: expanding availability of viable organs for transplantation
Year Founded
2005
First Award
2006
Latest Award
2016
Program Status
Inactive
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

20521 Bethelwood Lane
Cornelius, NC 28031
   (704) 892-4914
   emiescher@bellsouth.net
   www.hepatosys.com
Location: Single
Congr. District: 12
County: Mecklenburg

Public Profile

HepatoSys develops technologies for functional restoration of donor livers for use in transplantation and research, focusing on methods for expanding availability of quality human hepatocytes for research and toxicity testing.

Extent of SBIR involvement

User Avatar
Phase I Awards
4
Phase II Awards
1
Conversion Rate
25.00%
Phase I Dollars
$1,075,285
Phase II Dollars
$1,510,632
Total Awarded
$2,585,917

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2016 1 NIH $366,141
Project Title: Enhanced Production of Human Hepatocytes from Livers Declined for Transplant
2012 1 NIH $361,330
Project Title: Recovery Of Human Hepatocytes For Research And Drug Toxicity Screening From Cardi
2012 2 NIH $1,683,576
Project Title: Perfusion preservation solution for recovery of Donation by Cardiac Death livers
2006 1 NIH $174,870
Project Title: Recovery /preservation of donation cardiac death livers

Key People / Management

  Elizabeth Miescher-Clemens -- President

  Mark G Clemens -- Vice President and Chief Scientific Officer

  Mark G Clemens

  Kristin L Rogentine-Lee

Company News

Sep 11 2009
Turning research into profits